KRIBIOLISA™ Exenatide (Byetta) ELISA

Immunoassay for the quantitative determination of Exenatide in serum, plasma and cell culture supernatant Exenatide or Extendin-4 is a potent GLP-1 receptor agonist. Exenatide (marketed as Byetta) is one of a new class of medications (incretin mimetics) approved (in April 2005) for the treatment of diabetes mellitus type 2 (It was not approved for use in diabetes mellitus type 1). About the kit: - Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity. - Recovery rates are between 85 - 115% - Ready to use with a standard protocol with break-apart pre-coated wells - Validated as per US FDA guidelines for Bioassays - Optimized for matrix effects to ensure higher sensitivity. - Shelf life: 1 year The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Exenatide are pre-coated onto microwells. Samples and standards are pipetted into microwells and Exenatide present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti- Exenatide antibody is pipetted and incubated with samples. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Exenatide in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.